Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection in the world, and more than 90% of patients are infected with genotype 4 virus. We evaluated the efficacy and safety of the HCV polymerase inhibitor sofosbuvir in combination with ribavirin in HCV genotype 4 patients in Egypt.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Hepatol.

Title: Journal of hepatology

ISSN (Electronic): 1600-0641

ISSN (Print): 0168-8278

Publication date (Electronic): Sep 2015

Volume: 63

Issue: 3

Affiliations

[1 ] National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.

[2 ] Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. Electronic address: g_shiha@hotmail.com.

[3 ] Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.

[4 ] University of Cairo, Cairo, Egypt.

[5 ] Gilead Sciences, Inc., Foster City, CA, United States.

Article

Publisher Item ID: S0168-8278(15)00306-2

DOI: 10.1016/j.jhep.2015.04.023

PubMed ID: 25937436

SO-VID: 6501662a-684c-4ffa-a68f-66173974dede

History

Keywords: Antiviral agents,Egypt,Genotype 4,Hepatitis C,Polymerase inhibitor,Sofosbuvir

Data availability:

Keywords: Antiviral agents, Egypt, Genotype 4, Hepatitis C, Polymerase inhibitor, Sofosbuvir

Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.

Read this article at

Abstract

Related collections

Monkeypox

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 410

Cited by 40